Mehabe score: 6 G Factor: 5 Piotski Score: 8 The stock has a rating . The mehabe team score is reflective of its fundamental and technical merits. A rating above 8 is considered good buy. The stock has a G-Factor of 5 and Piotski score of 8.
Description
Nitta Gelatin India in the business of manufacture and sale of ossein, gelatin and collagen peptide.Site:506532Main Symbol:NITTAGELA
Stock trades at 226.0, above its 50dma 192.69. It also trades above its 200dma 172.26. The stock remains bullish on techicals
The 52 week high is at 225.00 and the 52week low is at 105.00
Price Chart
P/E Chart
Sales and Margin
Strengths
– Stock is trading at 1.18 times its book value
– has been maintaining a healthy dividend payout of 25.04%
Weakness
– The company has delivered a poor sales growth of 2.12% over past five years.
– has a low return on equity of 7.20% for last 3 years.
– might be capitalizing the interest cost
Competition
– The industry trades at a mean P/E of 29.6x. Pidilite Inds. trades at the industry’s max P/E of 102.58x. 506532 trades at a P/E of 11.8x
– Industry’s mean G-Factor is 3.9 while the mean Piotski score is 8.0. 506532 has a G-Factor of 5 and Piotski scoreof 8.
– Average 1 month return for industry is 7.0%. The max 1- month return was given by Nitta Gelatin: a return of 17.9 %
Quarterly Results
Sales for period ended Mar 2021 is Rs 105.05 cr compared to Rs 75.68 cr for period ended Mar 2020, a rise of 38.8%
Operating Profits reported at Rs 7.31 cr for period ended Mar 2021 vis-vis 3.43 for period ended Mar 2020 .
Operating Margins expanded 242.6 bps for period ended Mar 2021 vis-vis Mar 2020 .
The EPS for Mar 2021 was Rs 2.4 compared to Rs 7.03 for previous quarter ended Dec 2020 and Rs -1.19 for Mar 2020
Profit & Loss Statement
Profit&Loss Comments
Company reported sales of Rs 396.0 cr for period ended Mar 2021 vis-vis sales of Rs 342.0 cr for the period ended Mar 2020, a healthy growth of 13.6%. The 3 year sales cagr stood at 5.0%.
Operating margins expanded to 11.0% for period ended Mar 2021 vis-vis 10.0% for period ended Mar 2020, expansion of 100.0 bps.
Net Profit reported at Rs 17.0 cr for period ended Mar 2021 vis-vis sales of Rs 11.0 cr for the period ended Mar 2020, rising 35.3%.
Company recorded a healthy Net Profit CAGR of 62.0% over the last 3 years
Balance Sheet Statement
Cash Flow Statement
Cash Flow comments
CashFlow from operating activities was positive.
Sales Growth
Profit Growth Statement
Profit Growth Statement
Stock Price CAGR
Return of Equity
General Comments
– The company has improved its Return on Equity (RoE) metric. The RoE on Last Year basis was 11.0% compared to 7.0% over the last 3 Years. – The stock has given a return of 104% on a 1 Year basis vis-vis a return of 8% over the last 3 Years. – The compounded sales growth on a TTM bassis is 16% vis-vis a compounded sales growth of 5% over the last 3 Years. – The compounded profit growth on a TTM basis is 55% vis-vis a compounded profit growth of 58% over the last 3 Years.
Ratios
Shareholding Pattern
– Public shareholding has remained largely constant. The Mar 2021 public holding stood at 25.4% vis-vis 25.4% for Dec 2020
Conclusion
– Stock is trading at 1.18 times its book value
– has been maintaining a healthy dividend payout of 25.04% – The company has delivered a poor sales growth of 2.12% over past five years.
– has a low return on equity of 7.20% for last 3 years.
– might be capitalizing the interest cost
